Mixed trend on the daily chart: below its 200-day average, above its 50-day · 50-day below the 200-day · SuperTrend up since Jul 15 · above the Ichimoku cloud · RSI 58 · MACD above its signal
None of the 29 investors followed here reported a position in 1951.HK in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a 1951.HK trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 23, 2025 | Dong (Yang)Chief Executive Officer | Acquisition at price 0.33 per share. | 500K | $164.70K |
| Oct 14, 2025 | Dong (Yang)Chief Executive Officer | Acquisition at price 0.33 per share. | 500K | $164.60K |
| Aug 30, 2025 | Dong (Yang)Chief Executive Officer | — | 625.8K | — |
| Aug 30, 2025 | Lyu (Rong)Co-Chief Executive Officer | — | 1.11M | — |
| Aug 25, 2025 | Dong (Yang)Chief Executive Officer | Acquisition at price 0.41 per share. | 2.78M | $1.14M |
| Dec 30, 2024 | Zhong (Yong Cpa)Chairman of the Board | — | 1.30M | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 2.5 | 2.5 | -4.8 | 0.4 | -6.3 | -12.1 | 10.2 | 2.3 | 0.9 | 1.6 | −4.4% | ||
| 2025 | -9.0 | 7.4 | 14.9 | -3.3 | -3.4 | 8.9 | 8.8 | -13.5 | -0.7 | -14.0 | -2.8 | -0.4 | −11.2% |
| 2024 | -35.2 | 12.0 | 0.0 | 9.5 | 18.0 | -11.5 | -9.4 | -6.0 | 54.4 | -5.7 | -13.3 | -10.4 | −20.0% |
| 2023 | 0.8 | -14.2 | -15.7 | -2.1 | -21.4 | 2.2 | 8.7 | -12.9 | -4.6 | 5.1 | -4.6 | -10.7 | −53.5% |
| 2022 | -10.9 | 17.1 | -33.7 | -16.9 | 23.0 | 17.4 | -15.6 | -15.9 | -25.0 | 0.5 | 56.3 | 19.2 | −17.2% |
| 2021 | -0.4 | 11.9 | -4.6 | 19.6 | 11.8 | -12.3 | -25.6 | -15.2 | -6.1 | -5.0 | -1.1 | -20.1 | −44.6% |
| 2020 | 0.6 | -4.7 | -13.9 | 15.0 | 5.0 | 13.1 | -7.8 | 1.1 | -10.8 | -3.7 | 43.8 | 16.3 | +50.9% |
| 2019 | 11.2 | -2.0 | 19.2 | 27.1 | -17.6 | -12.4 | +19.2% |
Jinxin Fertility Group Limited, an investment holding company, provides assisted reproductive services (ARS) in China and internationally. The company provides two treatment solutions, including artificial insemination that is performed with either husband's sperm or a donor sperm; and IVF technology, whereby fertilization is achieved through conventional in vitro fertilization and embryo transfer or IVF with intracytoplasmic sperm injection. It also related services, such as nutrition guidance, Chinese medicine treatment, and psychological counseling to support the ARS. In addition, the company offers management services; obstetrics, gynecology, urology, internal medicine, and pediatrics medical services; ambulatory surgery center facilities services; and ancillary medical services. Further, it provides pre-implantation genetic screening testing, management consultancy, postpartum and rehabilitation care, maternal-child nursing, and other hospital- derived services. Additionally, the company is involved in property investment, and real estate development and operation activities; sale of medicines, consumables, and equipment; research and development of IVF related projects, including scientific research and related commercialization; and operates restaurant. Jinxin Fertility Group Limited was founded in 1951 and is headquartered in Chengdu, China.
Buy / hold / sell counts
No recent headlines.